Polyphenols, Blood Sugar, and Cardiovascular Health

Evidence Review

El-Saber Batiha et al. (2022) — Sumac's polyphenol profile [1]

This review in Molecules catalogued the phytochemical composition of Rhus coriaria across multiple plant parts, identifying over 200 bioactive compounds. The fruit fraction most relevant to culinary use is dominated by hydrolysable tannins (pentagalloylglucose, corilagin, geraniin), flavonoids (quercetin glycosides, kaempferol, myricetin), anthocyanins, and organic acids. The authors measured ORAC (oxygen radical absorbance capacity) values for sumac among the highest recorded for any food spice, exceeding turmeric and cloves in some assays. This phytochemical richness provides the mechanistic foundation for the clinical effects observed in human trials: tannin-derived gallic acid for glycemic control, quercetin and kaempferol for anti-inflammatory and cardiovascular effects, and anthocyanins for antioxidant protection of the vasculature.

Alsamri et al. (2021) — Pharmacological review [2]

This comprehensive review in Antioxidants synthesized the available evidence across sumac's pharmacological activities: antilipidemic, antidiabetic, antioxidant, anti-inflammatory, antihypertensive, antithrombotic, anticancer, and antimicrobial. The antioxidant activity of sumac extract was comparable to or exceeding that of common reference antioxidants (ascorbic acid, trolox) in standardized assays. The authors highlighted the tannin fraction as responsible for the majority of free radical scavenging, while the flavonoid fraction appeared to drive NF-kB inhibition and downstream anti-inflammatory signaling. The review called for more large-scale, long-duration human clinical trials while confirming that existing mechanistic and clinical data support sumac as a genuinely functional food spice.

Rahideh et al. (2014) — Sumac and insulin resistance in type 2 diabetes [3]

This double-blind, placebo-controlled RCT (n=41; 20 sumac, 21 placebo) assigned stable type 2 diabetic patients to either 3 g/day sumac powder or placebo for 3 months. Baseline characteristics were matched between groups. The sumac group showed statistically significant improvements across five metabolic markers: fasting blood glucose, HOMA-IR (insulin resistance), malondialdehyde (lipid peroxidation), hs-CRP (systemic inflammation), and paraoxonase-1 activity. PON1 is an HDL-associated enzyme that hydrolyzes oxidized lipids and is a strong predictor of cardiovascular risk in diabetic patients — its improvement by sumac represents a meaningful clinical finding beyond glycemic control alone. The 3-month duration and simultaneous improvement across oxidative stress, inflammation, and glycemic markers support a broad metabolic effect rather than a single-pathway intervention.

Sabzghabaee et al. (2014) — Sumac and dyslipidemia in adolescents [4]

This triple-blinded, placebo-controlled RCT enrolled 72 obese adolescents (ages 12-18) with dyslipidemia, randomizing them to 500 mg sumac capsules three times daily (1.5 g/day total) or matching placebo for 4 weeks. Plasma levels of total cholesterol, LDL cholesterol, and triglycerides showed statistically significant reductions in the sumac group compared to placebo (P < 0.05 for between-group differences). HDL cholesterol did not change significantly, which the authors attributed to the short 4-week duration. The rapid lipid-lowering effect at a relatively low dose (1.5 g/day) suggests potent HMG-CoA reductase inhibitory activity from the tannin fraction. The pediatric population is clinically notable given rising rates of dyslipidemia in overweight adolescents. Limitations include short duration and a single study population; longer-term effects on HDL and cardiovascular endpoints remain to be established.

Kazemi et al. (2020) — Sumac in non-alcoholic fatty liver disease [5]

This RCT enrolled 84 NAFLD patients (confirmed by ultrasound; 42 per group), all of whom followed a 500-calorie deficit diet, randomizing the intervention group to receive an additional 2 g/day sumac powder for 12 weeks. The sumac group showed statistically significant improvements compared to placebo in: ALT, AST, hepatic fibrosis score, fasting blood glucose, serum insulin, HbA1c, HOMA-IR, malondialdehyde, hs-CRP, and insulin sensitivity (QUICKI index). The fact that improvements in hepatic fibrosis — not just liver enzymes — were measured is particularly meaningful, as fibrosis is the primary determinant of long-term NAFLD prognosis and progression to cirrhosis. The breadth of simultaneous improvement across liver, glycemic, oxidative, and inflammatory markers at 2 g/day (lower than the 3 g/day used in the diabetes trial) suggests dose-dependent efficacy and positions sumac as a practical adjunct to lifestyle intervention in metabolic liver disease.

Mirenayat et al. (2023) — Sumac in metabolic syndrome [6]

This triple-blinded, randomized, placebo-controlled crossover trial (n=47; mean age 58.7 years, 81% female) enrolled adults with metabolic syndrome and assigned them to 500 mg sumac twice daily or placebo for 6-week periods separated by a 2-week washout. The primary finding was a significant reduction in systolic blood pressure in the sumac phase vs. placebo (123.2 vs. 128.8 mmHg; between-group difference: -5.59 mmHg, P=0.004). No significant effects were observed on diastolic BP, fasting glucose, insulin, HbA1c, lipid subfractions, or body composition, though per-protocol analysis showed a trend toward attenuated triglyceride rise (P=0.09). The selective effect on systolic blood pressure at a lower dose (1 g/day) and shorter duration (6 weeks) than the glycemic studies may indicate a threshold effect: cardiovascular outcomes appear at lower doses and shorter durations than metabolic benefits. The crossover design with washout period is a methodological strength, controlling for individual variation. The predominantly female study population (81%) limits generalizability to men.

Strength of evidence: Sumac has an unusually strong clinical evidence base for a culinary spice. Four independent RCTs — including one crossover design and two triple-blinded studies — demonstrate effects on glycemic control, lipid profiles, liver health, and blood pressure. Effect sizes are clinically meaningful (5-6 mmHg SBP reduction, significant improvements across multiple metabolic markers). The consistent dose range across effective studies is 1.5-3 g/day, easily achievable with daily culinary use. No adverse effects have been reported. The primary limitation is study size: most trials enrolled 40-85 participants. Replication in larger multicenter trials and longer follow-up (12+ months) would strengthen confidence in the sustained metabolic benefits suggested by this evidence base.